A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight ...

Eli Lilly has enlisted the aid of Tan France, fashion guru on the wildly popular US makeover show Queer Eye, in a campaign ...

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...

Hampton followed up with a thought about the Treat and Reduce Obesity Act (TROA) — a bipartisan bill in the U.S. Congress ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone amylin that slows digestion and reduces hunger.